IN182468B - - Google Patents

Info

Publication number
IN182468B
IN182468B IN102MA1996A IN182468B IN 182468 B IN182468 B IN 182468B IN 102MA1996 A IN102MA1996 A IN 102MA1996A IN 182468 B IN182468 B IN 182468B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN182468(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IN182468B publication Critical patent/IN182468B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IN102MA1996 1995-01-20 1996-01-19 IN182468B (enEXAMPLES)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
IN182468B true IN182468B (enEXAMPLES) 1999-04-17

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
IN102MA1996 IN182468B (enEXAMPLES) 1995-01-20 1996-01-19

Country Status (40)

Country Link
US (1) US6107302A (enEXAMPLES)
EP (1) EP0804436B1 (enEXAMPLES)
JP (1) JP3176633B2 (enEXAMPLES)
KR (1) KR100376074B1 (enEXAMPLES)
CN (1) CN1049893C (enEXAMPLES)
AP (1) AP662A (enEXAMPLES)
AR (1) AR002270A1 (enEXAMPLES)
AT (1) ATE302777T1 (enEXAMPLES)
AU (1) AU702794B2 (enEXAMPLES)
BG (1) BG63393B1 (enEXAMPLES)
BR (1) BR9606768A (enEXAMPLES)
CA (1) CA2210799C (enEXAMPLES)
CY (1) CY2531B1 (enEXAMPLES)
CZ (1) CZ297065B6 (enEXAMPLES)
DE (1) DE69635106T2 (enEXAMPLES)
DK (1) DK0804436T3 (enEXAMPLES)
EA (1) EA000364B1 (enEXAMPLES)
EE (1) EE03528B1 (enEXAMPLES)
ES (1) ES2248806T3 (enEXAMPLES)
FI (1) FI973063A7 (enEXAMPLES)
GB (1) GB9501178D0 (enEXAMPLES)
GE (1) GEP20001940B (enEXAMPLES)
HR (1) HRP960024B1 (enEXAMPLES)
HU (1) HU222993B1 (enEXAMPLES)
IL (1) IL116831A (enEXAMPLES)
IN (1) IN182468B (enEXAMPLES)
IS (1) IS2268B (enEXAMPLES)
NO (1) NO315558B1 (enEXAMPLES)
NZ (1) NZ298851A (enEXAMPLES)
OA (1) OA10499A (enEXAMPLES)
PL (1) PL182175B1 (enEXAMPLES)
RO (1) RO118693B1 (enEXAMPLES)
RS (1) RS49518B (enEXAMPLES)
SI (1) SI0804436T1 (enEXAMPLES)
SK (1) SK285329B6 (enEXAMPLES)
TR (1) TR199700656T1 (enEXAMPLES)
UA (1) UA46001C2 (enEXAMPLES)
UY (1) UY25779A1 (enEXAMPLES)
WO (1) WO1996022291A1 (enEXAMPLES)
ZA (1) ZA96449B (enEXAMPLES)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CN1250449A (zh) * 1997-01-17 2000-04-12 味之素株式会社 新型z－伐昔洛韦结晶
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
US6849736B2 (en) * 2001-09-07 2005-02-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
US7846937B2 (en) * 2005-05-25 2010-12-07 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR102018038B1 (ko) 2010-06-24 2019-09-05 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
NZ747331A (en) 2016-06-10 2025-06-27 Boehringer Ingelheim Int Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
CZ229497A3 (en) 1997-12-17
BR9606768A (pt) 1997-12-30
PL321326A1 (en) 1997-12-08
KR19980701525A (ko) 1998-05-15
RO118693B1 (ro) 2003-09-30
CZ297065B6 (cs) 2006-08-16
HRP960024A2 (en) 1997-10-31
RS49518B (sr) 2006-10-27
YU3396A (sh) 1998-12-23
AU702794B2 (en) 1999-03-04
SK96597A3 (en) 1998-02-04
SK285329B6 (sk) 2006-11-03
EP0804436B1 (en) 2005-08-24
AR002270A1 (es) 1998-03-11
AP9701058A0 (en) 1997-10-31
IL116831A (en) 1998-10-30
GEP20001940B (en) 2000-02-05
ZA96449B (en) 1996-08-07
CA2210799A1 (en) 1996-07-25
HRP960024B1 (en) 2005-08-31
FI973063A0 (fi) 1997-07-18
DK0804436T3 (da) 2005-12-27
EE03528B1 (et) 2001-10-15
JP3176633B2 (ja) 2001-06-18
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
NO315558B1 (no) 2003-09-22
EA199700124A1 (ru) 1997-12-30
CN1179159A (zh) 1998-04-15
ATE302777T1 (de) 2005-09-15
AU4453996A (en) 1996-08-07
NO973326L (no) 1997-09-16
CA2210799C (en) 2008-06-10
NO973326D0 (no) 1997-07-18
NZ298851A (en) 1999-01-28
HUP9801836A2 (hu) 1999-05-28
UA46001C2 (uk) 2002-05-15
SI0804436T1 (sl) 2006-02-28
DE69635106D1 (de) 2005-09-29
IL116831A0 (en) 1996-05-14
AP662A (en) 1998-08-19
ES2248806T3 (es) 2006-03-16
FI973063L (fi) 1997-09-18
EA000364B1 (ru) 1999-06-24
WO1996022291A1 (en) 1996-07-25
FI973063A7 (fi) 1997-09-18
HUP9801836A3 (en) 1999-06-28
GB9501178D0 (en) 1995-03-08
UY25779A1 (es) 2000-08-21
JPH11503718A (ja) 1999-03-30
BG101833A (bg) 1998-04-30
IS2268B (is) 2007-07-15
TR199700656T1 (xx) 1998-03-21
HU222993B1 (hu) 2004-01-28
EP0804436A1 (en) 1997-11-05
EE9700175A (et) 1998-02-16
DE69635106T2 (de) 2006-06-08
IS4527A (is) 1997-07-15
MX9705462A (es) 1997-10-31
CY2531B1 (en) 2006-04-12
OA10499A (en) 2002-04-10
US6107302A (en) 2000-08-22
PL182175B1 (pl) 2001-11-30
KR100376074B1 (ko) 2003-06-02

Similar Documents

Publication Publication Date Title
IN188469B (enEXAMPLES)
EP0760222A3 (enEXAMPLES)
IN183382B (enEXAMPLES)
IN186322B (enEXAMPLES)
IN185854B (enEXAMPLES)
IN184884B (enEXAMPLES)
IN184698B (enEXAMPLES)
IN184621B (enEXAMPLES)
IN183494B (enEXAMPLES)
IN183421B (enEXAMPLES)
IN182756B (enEXAMPLES)
CN3035868S (enEXAMPLES)
CN3034524S (enEXAMPLES)
EP0876296A4 (enEXAMPLES)
EP0730349A3 (enEXAMPLES)
CN3037560S (enEXAMPLES)
CN3037433S (enEXAMPLES)
CN3037189S (enEXAMPLES)
CN3036648S (enEXAMPLES)
CN3036647S (enEXAMPLES)
CN3036463S (enEXAMPLES)
CN3035871S (enEXAMPLES)
CN3035870S (enEXAMPLES)
CN3035869S (enEXAMPLES)
CN3031350S (enEXAMPLES)